Gynecologic Oncology Practice Questions

Q: A 36-year-old woman presents with vaginal bleeding, nausea, and pelvic pain. Her uterus is larger than expected for gestational age, and fetal heart tones are absent. Which of the following is most likely to be true?

b-hCG levels will be higher than normal. **Explanation:** The clinical presentation of vaginal bleeding, nausea (hyperemesis), a uterus "larger than dates," and absent fetal heart tones is classic for a **Hydatidiform Mole (Molar Pregnancy)**, a type of Gestational Trophoblastic Disease (GTD). **1. Why Option A is Correct:** In a complete hydatidiform mole, there is abnormal proliferation of trophoblastic tissue (specifically syncytiotrophoblasts). Since these cells are responsible for secreting **beta-hCG**, the levels are characteristically **markedly elevated** (often >100,000 mIU/mL). This extreme elevation is responsible for the exaggerated pregnancy symptoms like severe nausea/vomiting and the development of theca lutein cysts. **2. Why the Other Options are Incorrect:** * **Option B:** Low b-hCG levels are typically associated with ectopic pregnancies or threatened/inevitable abortions, not molar pregnancies. * **Option C:** In approximately 50% of complete mole cases, the uterus is **larger than expected** for gestational age due to the rapid proliferation of chorionic villi and accumulated blood (clots) within the uterine cavity. * **Option D:** High levels of b-hCG have a structural similarity to TSH (sharing the same alpha subunit). This causes b-hCG to act as a weak thyroid stimulator, leading to increased T3/T4 and a **decreased (suppressed) TSH** level, potentially causing clinical hyperthyroidism. **Clinical Pearls for NEET-PG:** * **USG Finding:** "Snowstorm appearance" or "Bunch of grapes" appearance (vesicular pattern). * **Karyotype:** Complete Mole is most commonly **46, XX** (diploid, purely paternal origin); Partial Mole is **69, XXY** (triploid). * **Complication:** Risk of progression to Choriocarcinoma is higher in complete moles (up to 15-20%). * **Management:** Suction and evacuation is the treatment of choice, followed by weekly b-hCG monitoring until three consecutive negative results are obtained.

Q: What defines an unsatisfactory colposcopy?

Failure to visualize the transformation zone. ### Explanation In colposcopy, the primary goal is to identify pre-malignant lesions (CIN). Most cervical neoplasias originate in the **Transformation Zone (TZ)**—the area between the original squamocolumnar junction (SCJ) and the new SCJ. **Why Option B is Correct:** A colposcopy is labeled **unsatisfactory** (or "inadequate") if the colposcopist cannot visualize the **entire transformation zone**, including the full 360-degree extent of the new squamocolumnar junction. If the SCJ has recessed into the endocervical canal (common in postmenopausal women), the examiner cannot rule out lesions hidden within the canal, making the exam inconclusive for excluding malignancy. **Analysis of Incorrect Options:** * **Option A:** While the cervix must be seen to perform the procedure, "unsatisfactory" is a specific technical term referring to the visibility of the SCJ/TZ, not just the gross anatomy of the cervix. * **Options C & D:** Visualizing only one type of epithelium is insufficient. The clinical significance lies in the **junction** where these two cell types meet (the TZ), as this is the site of greatest mitotic activity and HPV-induced oncogenesis. **High-Yield NEET-PG Pearls:** * **Management of Unsatisfactory Colposcopy:** If the TZ is not fully visible, the next step is typically an **Endocervical Curettage (ECC)** or a diagnostic excisional procedure (LEEP/Cold Knife Conization). * **Green Filter:** Used during colposcopy to highlight vascular patterns (punctations, mosaicism, atypical vessels). * **Acetic Acid (3-5%):** Causes dehydration of cells; areas with high nuclear-cytoplasmic ratios (dysplasia) appear white (**Acetowhite**). * **Schiller’s Test:** Uses Lugol’s iodine. Normal squamous cells (rich in glycogen) turn mahogany brown; dysplastic cells (glycogen depleted) remain **unstained (Iodine negative)**.

Q: All are risk factors for carcinoma endometrium EXCEPT?

Multiple sexual partners. **Explanation:** The core pathophysiology of **Endometrial Carcinoma (Type I)** is **unopposed estrogen stimulation**. Any condition that increases lifetime exposure to estrogen or leads to chronic anovulation increases the risk of endometrial hyperplasia and subsequent malignancy. * **Why Option B is the correct answer:** **Multiple sexual partners** is a risk factor for **Cervical Cancer**, not endometrial cancer. Cervical cancer is primarily caused by persistent infection with High-Risk Human Papillomavirus (HPV), a sexually transmitted infection. Endometrial cancer is generally not associated with sexual behavior or viral infections. * **Why the other options are incorrect (Risk Factors):** * **Infertility (Option A):** Infertility is often associated with **anovulatory cycles** (e.g., PCOS). In the absence of ovulation, there is no corpus luteum to produce progesterone. This leads to "unopposed estrogen," which causes endometrial proliferation. * **Diabetes (Option C) & Hypertension (Option D):** These are classic components of the **"Corpus Uteri Cancer Syndrome"** (Obesity, Diabetes, and Hypertension). Obesity leads to increased peripheral conversion of androstenedione to estrone in adipose tissue, while hyperinsulinemia in diabetes may directly stimulate endometrial growth. **High-Yield Clinical Pearls for NEET-PG:** * **Protective Factors:** Combined Oral Contraceptive Pills (COCPs), smoking (decreases estrogen levels, though harmful otherwise), multiparity, and physical activity. * **Lynch Syndrome (HNPCC):** The most common hereditary cause of endometrial cancer. * **Tamoxifen:** A selective estrogen receptor modulator (SERM) that acts as an antagonist in the breast but an **agonist** in the uterus, increasing the risk of endometrial cancer. * **Triad of Risk:** Obesity, Diabetes, and Hypertension.

Q: Endometrial carcinoma with vaginal metastasis, what FIGO stage would it be?

Stage III b. **Explanation:** The FIGO staging for Endometrial Carcinoma was updated in 2023; however, for NEET-PG, the **FIGO 2009 staging** remains the primary reference for this specific classification. **Why Stage III B is correct:** Stage III represents the local and/or regional spread of the tumor. Specifically, **Stage III B** is defined by the involvement of the **vagina and/or the parametrium**. The presence of vaginal metastasis indicates that the tumor has extended beyond the uterus but remains within the pelvic cavity, fitting the criteria for III B. **Analysis of Incorrect Options:** * **Stage III A:** This stage involves the tumor invading the **serosa** of the corpus uteri and/or the **adnexa** (fallopian tubes/ovaries) by direct extension or metastasis. * **Stage III C:** This stage involves metastasis to the **pelvic and/or para-aortic lymph nodes**. It is further divided into III C1 (pelvic nodes) and III C2 (para-aortic nodes). * **Stage IV A:** This represents advanced spread where the tumor invades the **bladder mucosa and/or the bowel mucosa**. **High-Yield Clinical Pearls for NEET-PG:** 1. **Most Common Site of Distant Metastasis:** Lungs. 2. **Most Common Site of Local Recurrence:** Vaginal vault. 3. **Prognostic Factor:** The most important prognostic factor in endometrial cancer is the **histological grade and depth of myometrial invasion**. 4. **Lymphatic Spread:** The primary route of spread is via lymphatics; pelvic nodes are usually involved before para-aortic nodes. 5. **Risk Factor:** Unopposed estrogen (PCOS, Obesity, Tamoxifen use) is the classic precursor for Type I Endometrial Carcinoma.

Q: Which of the following is not seen in Cowden syndrome?

Multiparity. **Explanation:** **Cowden Syndrome** is an autosomal dominant condition caused by a mutation in the **PTEN gene** (a tumor suppressor gene). It is characterized by multiple hamartomas and an increased risk of various malignancies, most notably breast, thyroid, and **endometrial cancer**. **Why Multiparity is the correct answer:** The question asks for what is **not** typically associated with Cowden Syndrome in the context of endometrial cancer risk. **Multiparity** is a known **protective factor** against endometrial cancer because it reduces the lifetime exposure to "unopposed estrogen" through high levels of progesterone during pregnancy. In contrast, Cowden syndrome patients are at a significantly higher risk (up to 30% lifetime risk) of developing Type I endometrial carcinoma. **Why the other options are incorrect:** Options A, B, and C (**Diabetes mellitus, Hypertension, and Obesity**) constitute the classic **"Corpus Uteri Cancer Syndrome"** or the metabolic triad associated with endometrial cancer. * **Obesity:** Increases peripheral conversion of androstenedione to estrone in adipose tissue. * **Diabetes & Hypertension:** These are independent risk factors often co-existing with obesity that further predispose an individual to endometrial hyperplasia and malignancy. In a patient with Cowden Syndrome, these metabolic factors act synergistically with the PTEN mutation to further elevate the risk of gynecologic oncology. **High-Yield Clinical Pearls for NEET-PG:** * **PTEN Mutation:** Also associated with Bannayan-Riley-Ruvalcaba syndrome. * **Pathognomonic Sign:** Mucocutaneous lesions (Trichilemmomas, papillomatous papules, and acral keratoses). * **Cancer Risks:** Breast (85% risk), Thyroid (Follicular type), and Endometrium. * **Lhermitte-Duclos disease:** A rare cerebellar dysplastic gangliocytoma is a specific diagnostic criterion for Cowden Syndrome.

Q: What is the primary treatment for stage III carcinoma of the ovary?

Debulking surgery with tumor removal. **Explanation:** The primary treatment for advanced epithelial ovarian cancer (Stage III and IV) is **Cytoreductive Surgery (Debulking)** followed by systemic chemotherapy. **Why Option C is Correct:** In Stage III ovarian cancer, the disease has spread beyond the pelvis to the peritoneum and/or regional lymph nodes. The goal of surgery is not just organ removal, but **maximal cytoreduction**—removing as much visible tumor mass as possible. Reducing the tumor burden to "optimal" levels (residual nodules <1 cm) improves the efficacy of subsequent platinum-based chemotherapy and significantly enhances overall survival. **Why Options A and B are Incorrect:** * **Options A and B:** While a Total Abdominal Hysterectomy (TAH) and Bilateral Salpingo-Oophorectomy (BSO) are *components* of the surgery, they are insufficient on their own for Stage III. These options ignore the metastatic deposits on the omentum, bowel, and peritoneal surfaces. Simply removing the uterus and ovaries without addressing the extrapelvic spread (debulking) would result in a poor prognosis. **High-Yield Clinical Pearls for NEET-PG:** * **Standard of Care:** The "Gold Standard" is primary cytoreductive surgery + adjuvant chemotherapy (Paclitaxel + Carboplatin). * **Optimal Debulking:** Defined as residual disease <1 cm in maximum diameter. "Complete" debulking (no visible disease) offers the best prognosis. * **Interval Debulking:** If the patient is too ill or the tumor is unresectable initially, Neoadjuvant Chemotherapy (NACT) is given for 3 cycles, followed by surgery. * **Tumor Marker:** **CA-125** is the most important marker for monitoring treatment response and recurrence in epithelial ovarian cancer.

Q: An elderly female is diagnosed to have Ca cervix stage III B. What is the management of choice in this patient?

Intracavitary brachytherapy with external beam radiation. **Explanation:** The management of Carcinoma Cervix is primarily determined by the FIGO stage. Stage III B is defined by the involvement of the pelvic wall and/or presence of hydronephrosis or a non-functioning kidney. **1. Why Option D is Correct:** For **locally advanced cervical cancer (LACC)**, which includes Stages II B through IV A, the standard of care is **Concurrent Chemoradiotherapy (CCRT)**. This involves External Beam Radiation Therapy (EBRT) to treat the primary tumor and pelvic nodes, followed by Intracavitary Brachytherapy (ICBT) to deliver a high dose to the central tumor. Cisplatin is typically used as a radiosensitizer. In this question, Option D represents the definitive radiotherapy component of this management. **2. Why the other options are incorrect:** * **Options A & B (Wertheim and Schauta’s Hysterectomy):** These are radical surgical procedures. Surgery is generally reserved for **early-stage disease (Stage I to II A)**. In Stage III B, the disease has spread to the pelvic side walls, making it impossible to achieve clear surgical margins. * **Option C (Chemotherapy):** While chemotherapy is used concurrently with radiation in Stage III B, it is not used as a standalone primary treatment (except in palliative settings for Stage IV B). **Clinical Pearls for NEET-PG:** * **Stage II B** is the earliest stage where surgery is no longer the primary treatment (Parametrial involvement). * **Most common cause of death** in Ca Cervix: Uremia due to bilateral ureteric obstruction (Stage III B). * **Investigation of choice for staging:** MRI Pelvis (though FIGO staging remains clinical). * **Standard Radiosensitizer:** Weekly Cisplatin.

Q: Which of the following is related to prophylactic chemotherapy in molar pregnancy?

It may be given in 'at risk' patients. **Explanation:** Prophylactic chemotherapy in molar pregnancy is a controversial but recognized clinical strategy aimed at reducing the risk of progression to Gestational Trophoblastic Neoplasia (GTN). **Why Option A is Correct:** Prophylactic chemotherapy (usually with Methotrexate or Actinomycin-D) is indicated for patients categorized as **'high risk'** for malignant transformation, especially when reliable follow-up is unavailable. High-risk criteria include: * Pre-evacuation hCG levels >100,000 mIU/mL. * Excessive uterine size for gestational age. * Theca lutein cysts >6 cm. * Age >40 years. **Why Other Options are Incorrect:** * **Option B:** Single-agent chemotherapy (Methotrexate or Actinomycin-D) is the standard for prophylaxis. Multiple agents are reserved for high-risk metastatic GTN (e.g., EMA-CO regimen). * **Option C:** While it reduces the incidence of post-molar GTN (from ~15-20% down to 3-8%), it **does not eliminate** the risk entirely. Malignant sequelae can still occur. * **Option D:** Follow-up is **mandatory**. Prophylactic chemotherapy may actually mask the early rise of hCG or select for chemo-resistant trophoblastic cells, making strict serial hCG monitoring even more critical. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Management:** The primary treatment for a hydatidiform mole is **Suction and Evacuation**, regardless of the risk profile. * **Follow-up Gold Standard:** Weekly serum β-hCG levels until three consecutive normal values are obtained, followed by monthly levels for 6 months. * **Contraception:** Combined Oral Contraceptive Pills (COCs) are the preferred method during the follow-up period to avoid confusing a new pregnancy with GTN.

Question 1

What is the recommended treatment for a 50-year-old woman with biopsy-proven CIN 3?

Accepted Answer

Colposcopy with LEEP

Answer

Conization

Answer

Hysterectomy

Answer

Trachelectomy

Question 2

A 36-year-old woman presents with vaginal bleeding, nausea, and pelvic pain. Her uterus is larger than expected for gestational age, and fetal heart tones are absent. Which of the following is most likely to be true?

Accepted Answer

b-hCG levels will be higher than normal

Answer

b-hCG levels will be lower than normal

Answer

Uterus will be of normal size for gestational age

Answer

TSH levels will be increased

Question 3

A 40-year-old woman complains of irregular bleeding for 7 months after delivery of her fourth baby. Curettage is performed and histology reveals a choriocarcinoma. Her serum beta hCG level is 2x10^5 IU/L. What is the most appropriate next step in the management?

Accepted Answer

Commence treatment with multi-agent combination chemotherapy

Answer

Commence treatment with intramuscular methotrexate

Answer

Perform a hysterectomy

Answer

Repeat serum hCG after 4 weeks

Question 4

What defines an unsatisfactory colposcopy?

Accepted Answer

Failure to visualize the transformation zone

Answer

Failure to visualize the cervix

Answer

Failure to visualize the squamous epithelium

Answer

Failure to visualize the columnar epithelium

Question 5

All are risk factors for carcinoma endometrium EXCEPT?

Accepted Answer

Multiple sexual partners

Answer

Infertility

Answer

Diabetes

Answer

Hypertension

Question 6

Endometrial carcinoma with vaginal metastasis, what FIGO stage would it be?

Accepted Answer

Stage III b

Answer

Stage III a

Answer

Stage III c

Answer

Stage IV a

Question 7

Which of the following is not seen in Cowden syndrome?

Accepted Answer

Multiparity

Answer

Diabetes mellitus

Answer

Hypertension

Answer

Obesity

Question 8

What is the primary treatment for stage III carcinoma of the ovary?

Accepted Answer

Debulking surgery with tumor removal

Answer

Total hysterectomy

Answer

Total hysterectomy and bilateral salpingo-oophorectomy

Answer

None of the above

Question 9

An elderly female is diagnosed to have Ca cervix stage III B. What is the management of choice in this patient?

Accepted Answer

Intracavitary brachytherapy with external beam radiation

Answer

Wertheim hysterectomy

Answer

Shautas procedure

Answer

Chemotherapy

Question 10

Which of the following is related to prophylactic chemotherapy in molar pregnancy?

Accepted Answer

It may be given in 'at risk' patients

Answer

Multiple agents are preferred

Answer

Malignant sequelae becomes nil

Answer

Follow-up is not required

Gynecologic Oncology — MCQs

Gynecologic Oncology — MCQs

On this page

Practice by Chapter

Want unlimited practice?